Interactive Light Technology Enhances Engagement for Dementia Patients

A company situated in Kent is employing light technology to interact with individuals affected by dementia. Social-Ability, based in Tonbridge, supplies interactive light systems to healthcare facilities and residential care homes. These systems feature interactive games designed for projection onto various surfaces, including tables, walls, and ceilings. John Ramsay, the managing director, stated, “It’s possible for people living with dementia to lead happy, fulfilling lives when they’re supported with the right resources.” According to the company, individuals utilizing its technology have experienced notable enhancements in social wellbeing, while care homes have observed a decrease in the administration of antipsychotic medications following its implementation. A company representative explained that by stimulating senses within pleasant surroundings, these light-based activities can facilitate memory recall and contribute to genuine happiness for users. Mr. Ramsay’s motivation stemmed from his personal experience of providing care for his father, who suffered from dementia. He further commented, “We are tapping into the joy and happiness that still exists for people with dementia,” and added, “Our technology with interactive lights is creating incredible engagement.” Mickayla Lawrie, who manages Avery Healthcare’s Guildford House Care Home, remarked, “It really gets them out of their comfort zone. It brings everyone together but it also helps us with our carers. Everyone can get involved.” Research conducted by the NHS indicates that over 944,000 individuals in the UK, representing one in every 11 people aged over 65, are living with dementia. This figure is rising as lifespans extend. Projections suggest that by the year 2030, the population affected by dementia in the UK will exceed one million. The Alzheimer’s Society notes that antipsychotic medications may be prescribed for individuals with dementia who exhibit behavioral changes like aggression and psychosis, though typically only subsequent to trials of other pharmaceutical interventions.